Chemical Information
Antiviral agent ID	DrugRepV_4410
Antiviral agent name	6-bromo-2-oxo-N-3-pyridinyl-2H-chromene-3-carboxamide
IUPAC Name	6-bromo-2-oxo-N-3-pyridinyl-2H-chromene-3-carboxamide
SMILES (canonical)	C1=CC(=CN=C1)NC(=O)C2=CC3=C(C=CC(=C3)Br)OC2=O
Molecular Formula	C15H9BrN2O3
Molecular Weight (g/mol)	345.1
InChl	InChI=1S/C15H9BrN2O3/c16-10-3-4-13-9(6-10)7-12(15(20)21-13)14(19)18-11-2-1-5-17-8-11/h1-8H,(H,18,19)
Structural Information
Clinical Information
Biological Information
Secondary Indication	Hendra virus (HeV) NA F0, amino acids 105 to 114
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	293FT
Secondary Indication (Viral titer)	1 μM
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Drug concentration)	40 μM
Secondary Indication (Cell based assay)	CatL-Peptide cleavage
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	Percentage inhibition [ 32.65 % ]
Reference	Elshabrawy HA, Fan J, Haddad CS, Ratia K, Broder CC, Caffrey M, Prabhakar BS..Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay..J Virol. 2014 Apr;88(8):4353-65. doi: 10.1128/JVI.03050-13. Epub 2014 Feb 5. PubMed Central PMCID: P PMID:24501399
Comment	A novel broad-spectrum small molecule that could block cathepsin L-mediated cleavage was identified and thus inhibit the entry of pseudotypes bearing the glycoprotein derived from SARS-CoV or Ebola, Hendra, or Nipah virus. The small molecule can be further optimized and developed into a potent broad-spectrum antiviral drug.